Proposed minimum requirements for market approval of continuous glucose monitoring (CGM) systems: A viewpoint from the IFCC working group on CGM.

IF 5.4 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes, Obesity & Metabolism Pub Date : 2025-04-28 DOI:10.1111/dom.16420

Stefan Pleus, Manuel Eichenlaub, Elisabet Eriksson Boija, Peter Diem, Marion Fokkert, Rolf Hinzmann, Johan Jendle, David C Klonoff, Konstantinos Makris, James H Nichols, John Pemberton, Elizabeth Selvin, Robbert J Slingerland, Andreas Thomas, Nam K Tran, Lilian Witthauer, Guido Freckmann

引用次数: 0

查看原文本刊更多论文

持续血糖监测（CGM）系统市场批准的拟议最低要求：IFCC CGM工作组的观点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Obesity & Metabolism 医学-内分泌学与代谢

CiteScore

10.90

自引率

6.90%

发文量

319

审稿时长

3-8 weeks

期刊介绍： Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.